NCT02937272 2025-10-20
A Study of LY3200882 in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Clinical Trials
5 trialsNCT02791334 2024-09-27
PACT
Eli Lilly and Company
Phase 1 Completed
NCT03099109 2023-10-17
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT03495323 2021-04-15
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03343613 2020-06-09
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated